Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar;8(1):26-31.
doi: 10.18502/cmm.8.1.9211.

Antifungal activity of Taurolidine against Mucorales: An in vitro study on clinical isolates

Hadis Jafarian  1 , Ali Amanati  2   3 , Parisa Badiee  1
Affiliations

Antifungal activity of Taurolidine against Mucorales: An in vitro study on clinical isolates

Hadis Jafarian et al. Curr Med Mycol. 2022 Mar.

Abstract

Background and purpose: Taurolidine is active against a wide variety of micro-organisms, including bacteria and fungi. Mucormycosis is one of the life-threatening opportunistic fungal infections, especially in immunocompromised patients. Currently, the emergence of Mucormycosis during the COVID-19 pandemic raises public health concerns regarding untoward morbidity and mortality among SARS-CoV-2 patients. It is well-known that delayed and inappropriate antifungal therapy leads to increased morbidity and mortality. This study aimed to investigate the in-vitro antifungal activity of taurolidine to evaluate its effects against clinical isolates of Mucorales.

Materials and methods: This study included previously collected clinical Mucorales isolates. The minimum in vitro inhibitory concentration (MIC) of amphotericin B, caspofungin, voriconazole, posaconazole, and itraconazole was determined using the broth microdilution method.

Results: All clinical isolates showed full sensitivity to amphotericin B. Posaconazole MIC range from 8 μg/mL to 0.032‎ μg/mL. The MIC range of voriconazole and caspofungin were determined to be 2-8 µg/mL and 0.5-16 µg/mL, respectively. Growth of the isolates was entirely inhibited in 1000 µg/mL concentration of taurolidine. In microscopic observations, morphological effects on hyphal growth were observed at 500 µg/mL concentration.

Conclusion: In conclusion, this is an updated experience of using taurolidine against Mucorales. However, our in-vitro findings need to be confirmed in well-designed clinical trials aimed at treating invasive Mucormycosis infections.

Keywords: Minimum inhibitory concentrations; Mucormycosis; Taurolidine; Mucorales.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have influenced the work reported in any way.

Figures

Figure 1
Figure 1
Light microscopic observations of tested isolates exposed to taurolidine. Dense and normal hyphal growth in control well
Figure 2
Figure 2
Slight morphological effect in 250 ‎µg/ml‎ concentration
Figure 3
Figure 3
Short, distended, and balloon-shaped hyphae in 500 ‎µg/ml‎ concentration
Figure 4
Figure 4
Complete growth inhibition in 1000 ‎µg/ml‎ concentration
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Browne MK. Pharmacological and clinical studies on Taurolin. a new concept in antimicrobial chemotherapy for surgical infection. United States: Urban & Schwarzenberg; 1985.
    1. Gorman SP, McCafferty DF, Woolfson AD, Jones DS. Reduced adherence of micro‐organisms to human mucosal epithelial cells following treatment with Taurolin, a novel antimicrobial agent. J Appl Bacteriol. 1987; 62(4):315–20. - PubMed
    1. Torres-Viera C, Thauvin-Eliopouls C, Souli M, DeGirolami P, Farris MG, Wennersten CB, et al. Activities of taurolidine in vitro and in experimental enterococcal endocarditis. Antimicrob Agents Chemother. 2000; 44(6):1720–24. - PMC - PubMed
    1. Gorman SP, McCafferty DF, Woolfson AD, Jones DS. Electron and light microscopic observations of bacterial cell surface effects due to taurolidine treatment. Lett Appl Microbio. 1987; 4(5):103–9.
    1. Handrup MM, Moller JK, Schroder H. Central venous catheters and catheter locks in children with cancer: a prospective randomized trial of taurolidine versus heparin. Pediatr Blood Cancer. 2013; 60(8):1292–8. - PubMed

LinkOut - more resources